| dc.creator | Enria, Delia | |
| dc.creator | Maiztegui, Julio I. | |
| dc.date | 2020-12-18T16:03:13Z | |
| dc.date | 2020-12-18T16:03:13Z | |
| dc.date | 1994-01 | |
| dc.date.accessioned | 2023-08-29T20:08:02Z | |
| dc.date.available | 2023-08-29T20:08:02Z | |
| dc.identifier | 0166-3542 | |
| dc.identifier | http://sgc.anlis.gob.ar/handle/123456789/1952 | |
| dc.identifier | 10.1016/0166-3542(94)90030-2 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/8519966 | |
| dc.description | Fil: Enria, Delia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina. | |
| dc.description | Fil: Maiztegui, Julio I. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas; Argentina. | |
| dc.description | Argentine hemorrhagic fever is a systemic viral disease caused by Junin virus, with a mortality of 15-30% in untreated individuals. Current specific therapy is highly effective in reducing mortality, and consists of the early administration of immune plasma in defined doses of specific neutralizing antibodies per kg of body weight. However, several reasons suggest the need to investigate alternative therapies. Ribavirin, a broad spectrum antiviral agent, is effective in the treatment of other viral hemorrhagic fevers, and the studies done with Junin virus infections to date indicate that this drug may also have a beneficial effect in Argentine hemorrhagic fever. | |
| dc.language | en | |
| dc.publisher | Elsevier | |
| dc.relation | Antiviral research | |
| dc.rights | open | |
| dc.source | Antiviral Research 1994; 23(1):23-31. | |
| dc.subject | Fiebre Hemorrágica Americana | |
| dc.subject | Argentina | |
| dc.subject | Antivirales | |
| dc.title | Antiviral treatment of Argentine hemorrhagic fever | |
| dc.type | Artículo | |
